本文以Lo and Mackinlay(1988,1989)[1][2]的方差比率为基础,构建了考察股市噪音成分的MCT指标,并对亚洲七个国家和地区的股市进行了检验。结果发现中国大陆和泰国股市具有更大的噪音成分,市场效率性较差;香港地区、台湾和日本股市则具...本文以Lo and Mackinlay(1988,1989)[1][2]的方差比率为基础,构建了考察股市噪音成分的MCT指标,并对亚洲七个国家和地区的股市进行了检验。结果发现中国大陆和泰国股市具有更大的噪音成分,市场效率性较差;香港地区、台湾和日本股市则具有较小的噪音交易成分,且无法拒绝不存在噪音交易的零假设;马来西亚和印度尼西亚的市场表现则处于前两者之间。最后我们通过Bootstrap对检验进行了重新评估,发现本文的检验结果是稳健的。展开更多
During the implementation of clinical trials NCT00950001 and NCCTG/N107C/CEC.3 on post-operative stereotactic radiosurgery into clinic, it brought us some thinking of fundamental concept in science that the local cont...During the implementation of clinical trials NCT00950001 and NCCTG/N107C/CEC.3 on post-operative stereotactic radiosurgery into clinic, it brought us some thinking of fundamental concept in science that the local control rate and survival rate rely on the treatment of marginal region more than resection cavity. Marginal region might still contain residual cancer cell while the resection cavity contains only water fluid most time. Radiation treatment should focus more on the margin rather than the cavity, thus treating cancer rather than water.展开更多
Objective:NCT01780675,a multicenter randomized phase III trial of prophylactic cranial irradiation(PCI)versus PCI with hippocampal sparing in small cell lung cancer(SCLC)investigated neurocognitive decline and safety....Objective:NCT01780675,a multicenter randomized phase III trial of prophylactic cranial irradiation(PCI)versus PCI with hippocampal sparing in small cell lung cancer(SCLC)investigated neurocognitive decline and safety.As part of quality assurance,we evaluated if hippocampal avoidance(HA)-PCI was performed according to the NCT01780675 trial protocol instructions,and performed a safety analysis to study the incidence and location of brain metastases for patients treated with HA-PCI.Methods:This retrospective analysis evaluated the quality of the irradiation given in the randomized controlled trial(RCT)comparing SCLC patients receiving PCI with or without hippocampal avoidance,using intensity mod-ulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT).The dose distribution for each patient receiving HA-PCI was retrieved and analyzed to evaluate if the treatment dose constraints were met.A ques-tionnaire was sent out to all participating sites,and data on radiotherapy technique,pre-treatment dummy runs,phantom measurements and treatment electronic portal imaging device(EPID)dosimetry were collected and analyzed.As part of the safety analysis,the follow-up magnetic resonance imaging(MRI)or computerized to-mography(CT)scans on which cranial disease progression was first diagnosed were collected and matched to the radiotherapy planning dose distribution.The matched scans were reviewed to analyze the location of the brain metastases in relation to the prescribed dose.Results:A total of 168 patients were randomized in the NCT01780675 trial in 10 centers in the Netherlands and Belgium from April 2013 until March 2018.Eighty two patients receiving HA-PCI without evidence of brain metastases were analyzed.All patients were treated with 25 Gy in 10 fractions.Dummy runs and phantom measurements were performed in all institutions prior to enrolling patients into the study.The radiotherapy(RT)plans showed a median mean bilateral hippocampal dose of 8.0 Gy,range 5.4-11.4(constraint≤8.5 Gy).In six patients(7.3%)there was a protocol violation of the mean dose in one or both hippocampi.In four of these six patients(4.9%)the mean dose to both hippocampi exceeded the constraint,in 1 patient(1.2%)only the left and in 1 patient(1.2%)only the right hippocampal mean dose was violated(average median dose left and right 8.9 Gy).All patients met the trial dose constraint of V 115%PTV≤1%;however the D max PTV constraint of≤28.75 Gy was violated in 22.0%of the patients.The safety analysis showed that 14 patients(17.1%)developed cranial progression.No solitary brain metastases in the underdosed region were found.Two out of 11 patients with multiple brain metastasis developed metastasis in the underdosed region(s).Conclusions:The radiotherapy quality within the HA-PCI trial is performed according to the protocol guidelines.The dose constraints to the hippocampi are met in the vast majority of cases.In all patients,the volume of the brain for which a higher dose was accepted,is according to the trial.However,within this volume there are small areas with higher doses than advised.展开更多
In the article“MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma”(Oncology Research.2019 Jun 21;27(6):691-701,doi:10....In the article“MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma”(Oncology Research.2019 Jun 21;27(6):691-701,doi:10.3727/096504018X15426763753594),the IHC images for CXCL12 and Bcl-2 expressions in adjacent noncancer tissues(NCT)shown in Fig.5E were unintentionally duplicated.And Fig.5A,B was also unintentionally duplicated.These needed corrections to ensure the accuracy and integrity of the data presented.展开更多
文摘本文以Lo and Mackinlay(1988,1989)[1][2]的方差比率为基础,构建了考察股市噪音成分的MCT指标,并对亚洲七个国家和地区的股市进行了检验。结果发现中国大陆和泰国股市具有更大的噪音成分,市场效率性较差;香港地区、台湾和日本股市则具有较小的噪音交易成分,且无法拒绝不存在噪音交易的零假设;马来西亚和印度尼西亚的市场表现则处于前两者之间。最后我们通过Bootstrap对检验进行了重新评估,发现本文的检验结果是稳健的。
文摘During the implementation of clinical trials NCT00950001 and NCCTG/N107C/CEC.3 on post-operative stereotactic radiosurgery into clinic, it brought us some thinking of fundamental concept in science that the local control rate and survival rate rely on the treatment of marginal region more than resection cavity. Marginal region might still contain residual cancer cell while the resection cavity contains only water fluid most time. Radiation treatment should focus more on the margin rather than the cavity, thus treating cancer rather than water.
文摘Objective:NCT01780675,a multicenter randomized phase III trial of prophylactic cranial irradiation(PCI)versus PCI with hippocampal sparing in small cell lung cancer(SCLC)investigated neurocognitive decline and safety.As part of quality assurance,we evaluated if hippocampal avoidance(HA)-PCI was performed according to the NCT01780675 trial protocol instructions,and performed a safety analysis to study the incidence and location of brain metastases for patients treated with HA-PCI.Methods:This retrospective analysis evaluated the quality of the irradiation given in the randomized controlled trial(RCT)comparing SCLC patients receiving PCI with or without hippocampal avoidance,using intensity mod-ulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT).The dose distribution for each patient receiving HA-PCI was retrieved and analyzed to evaluate if the treatment dose constraints were met.A ques-tionnaire was sent out to all participating sites,and data on radiotherapy technique,pre-treatment dummy runs,phantom measurements and treatment electronic portal imaging device(EPID)dosimetry were collected and analyzed.As part of the safety analysis,the follow-up magnetic resonance imaging(MRI)or computerized to-mography(CT)scans on which cranial disease progression was first diagnosed were collected and matched to the radiotherapy planning dose distribution.The matched scans were reviewed to analyze the location of the brain metastases in relation to the prescribed dose.Results:A total of 168 patients were randomized in the NCT01780675 trial in 10 centers in the Netherlands and Belgium from April 2013 until March 2018.Eighty two patients receiving HA-PCI without evidence of brain metastases were analyzed.All patients were treated with 25 Gy in 10 fractions.Dummy runs and phantom measurements were performed in all institutions prior to enrolling patients into the study.The radiotherapy(RT)plans showed a median mean bilateral hippocampal dose of 8.0 Gy,range 5.4-11.4(constraint≤8.5 Gy).In six patients(7.3%)there was a protocol violation of the mean dose in one or both hippocampi.In four of these six patients(4.9%)the mean dose to both hippocampi exceeded the constraint,in 1 patient(1.2%)only the left and in 1 patient(1.2%)only the right hippocampal mean dose was violated(average median dose left and right 8.9 Gy).All patients met the trial dose constraint of V 115%PTV≤1%;however the D max PTV constraint of≤28.75 Gy was violated in 22.0%of the patients.The safety analysis showed that 14 patients(17.1%)developed cranial progression.No solitary brain metastases in the underdosed region were found.Two out of 11 patients with multiple brain metastasis developed metastasis in the underdosed region(s).Conclusions:The radiotherapy quality within the HA-PCI trial is performed according to the protocol guidelines.The dose constraints to the hippocampi are met in the vast majority of cases.In all patients,the volume of the brain for which a higher dose was accepted,is according to the trial.However,within this volume there are small areas with higher doses than advised.
文摘In the article“MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma”(Oncology Research.2019 Jun 21;27(6):691-701,doi:10.3727/096504018X15426763753594),the IHC images for CXCL12 and Bcl-2 expressions in adjacent noncancer tissues(NCT)shown in Fig.5E were unintentionally duplicated.And Fig.5A,B was also unintentionally duplicated.These needed corrections to ensure the accuracy and integrity of the data presented.
